Comparison
Cagrilintide vs. Hexarelin
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Metabolic
Growth
CAS no.
1415456-99-3
140703-51-1
Molecular weight
4253.7 g/mol
887.05 g/mol
Half-life
168 h
0.9 h
Sequence
KCNTATCATQRLANFLVRSSNNLGPVLPPTNVGSNTYHis-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2Mechanism of action
Cagrilintide
Cagrilintide binds amylin receptors (AMY1, AMY3, formed by the calcitonin receptor plus RAMP proteins). Activation delays gastric emptying, inhibits postprandial glucagon secretion and modulates central satiety signalling via area postrema neurons. An acyl modification enables albumin binding and thereby weekly dosing.
Hexarelin
Hexarelin is a synthetic analog of the GHRP-6 family binding both the GH secretagogue receptor (GHSR-1a) and CD36. GHSR activation in the pituitary releases pulsatile growth hormone. Via CD36 in endothelium and myocardium, cardioprotective effects have been described in animal studies.
Evidence base
Highest evidence
Human RCT
Human trial
Studies
4
4
of which in humans
3
3
Effects recorded
3
3
Open conflicts
0
0
Documented adverse events
1
1